{"id":60916,"date":"2020-12-31T14:31:14","date_gmt":"2020-12-31T17:31:14","guid":{"rendered":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/"},"modified":"2020-12-31T14:31:14","modified_gmt":"2020-12-31T17:31:14","slug":"china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm","status":"publish","type":"post","link":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/","title":{"rendered":"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm"},"content":{"rendered":"
\n
\n

A China aprovou a vacina contra covid-19 desenvolvida pela farmac\u00eautica estatal chinesa\u00a0Sinopharm<\/a>\u00a0para uso do p\u00fablico em geral. Ela \u00e9 a 1\u00aa que ser\u00e1 distribu\u00edda sem limita\u00e7\u00f5es no pa\u00eds. O imunizante j\u00e1 tinha autoriza\u00e7\u00e3o de uso limitado.<\/p>\n

\n

\n

Segundo a estatal, a vacina recebeu o aval na 4\u00aa feira (30.dez.2020). A informa\u00e7\u00e3o foi divulgada em entrevista concedida na manh\u00e3 desta 5\u00aa feira (31.dez). Eis a\u00a0\u00edntegra<\/a>, em chin\u00eas, (844 KB) da nota da farmac\u00eautica.<\/p>\n

O imunizante j\u00e1 havia recebido a aprova\u00e7\u00e3o definitiva pelos Emirados \u00c1rabes Unidos e pelo Bahrein. Saiba\u00a0aqui<\/a>\u00a0os 50 pa\u00edses que j\u00e1 come\u00e7aram a vacina\u00e7\u00e3o.<\/p>\n

A farmac\u00eautica chinesa havia\u00a0anunciado<\/a> na 4\u00aa feira (30.dez.2020) que a vacina tinha taxa de efic\u00e1cia de 79,34% contra a doen\u00e7a. O imunizante exige a aplica\u00e7\u00e3o de duas doses.<\/p>\n

A farmac\u00eautica desenvolve duas vacinas contra a covid-19, ambas usando a t\u00e9cnica de v\u00edrus inativado. A que foi aprovada foi desenvolvida com o Instituto de Produtos Biol\u00f3gicos de Pequim. O outro imunizante da farmac\u00eautica tem parceria com o Instituto de Produtos Biol\u00f3gicos de Wuhan.<\/p>\n

As duas vacinas da Sinopharm j\u00e1 eram usadas na China em casos especiais desde agosto. M\u00e9dicos, militares e diplomatas empregados no exterior foram vacinados.<\/p>\n

\n

O imunizante da Sinopharm n\u00e3o deve ser confundido com a vacina de outra farmac\u00eautica chinesa, a\u00a0Sinovac<\/a>, que produz a\u00a0CoronaVac<\/a>\u00a0(adquirida e desenvolvida no Brasil pelo\u00a0Instituto Butantan<\/a>, de S\u00e3o Paulo).<\/p>\n<\/div>\n<\/section>\n<\/section>\n

Via Poder 360<\/div>\n","protected":false},"excerpt":{"rendered":"

A China aprovou a vacina contra covid-19 desenvolvida pela farmac\u00eautica estatal chinesa\u00a0Sinopharm\u00a0para uso do p\u00fablico em geral. Ela \u00e9 a 1\u00aa que ser\u00e1 distribu\u00edda sem limita\u00e7\u00f5es no pa\u00eds. O imunizante j\u00e1 tinha autoriza\u00e7\u00e3o de uso limitado. Segundo a estatal, a vacina recebeu o aval na 4\u00aa feira (30.dez.2020). A informa\u00e7\u00e3o foi divulgada em entrevista concedida …<\/p>\n","protected":false},"author":2,"featured_media":60917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"facebook_2648258775420054_1618374048415101":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":"","_jetpack_memberships_contains_paid_content":false},"categories":[901,118],"tags":[8697,8698,8699,8341],"yoast_head":"\nChina aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm\" \/>\n<meta property=\"og:description\" content=\"A China aprovou a vacina contra covid-19 desenvolvida pela farmac\u00eautica estatal chinesa\u00a0Sinopharm\u00a0para uso do p\u00fablico em geral. Ela \u00e9 a 1\u00aa que ser\u00e1 distribu\u00edda sem limita\u00e7\u00f5es no pa\u00eds. O imunizante j\u00e1 tinha autoriza\u00e7\u00e3o de uso limitado. Segundo a estatal, a vacina recebeu o aval na 4\u00aa feira (30.dez.2020). A informa\u00e7\u00e3o foi divulgada em entrevista concedida …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/\" \/>\n<meta property=\"og:site_name\" content=\"Portal NPM\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-31T17:31:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Genival Barbosa\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Genival Barbosa\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/\",\"url\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/\",\"name\":\"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm\",\"isPartOf\":{\"@id\":\"https:\/\/portalnpm.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg\",\"datePublished\":\"2020-12-31T17:31:14+00:00\",\"dateModified\":\"2020-12-31T17:31:14+00:00\",\"author\":{\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294\"},\"breadcrumb\":{\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage\",\"url\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg\",\"contentUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg\",\"width\":600,\"height\":400},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/portalnpm.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/portalnpm.com\/#website\",\"url\":\"https:\/\/portalnpm.com\/\",\"name\":\"Portal NPM\",\"description\":\"Not\u00edcias em Primeira M\u00e3o\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/portalnpm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294\",\"name\":\"Genival Barbosa\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/portalnpm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg\",\"contentUrl\":\"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg\",\"caption\":\"Genival Barbosa\"},\"url\":\"https:\/\/portalnpm.com\/index.php\/author\/genival\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/","og_locale":"pt_BR","og_type":"article","og_title":"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm","og_description":"A China aprovou a vacina contra covid-19 desenvolvida pela farmac\u00eautica estatal chinesa\u00a0Sinopharm\u00a0para uso do p\u00fablico em geral. Ela \u00e9 a 1\u00aa que ser\u00e1 distribu\u00edda sem limita\u00e7\u00f5es no pa\u00eds. O imunizante j\u00e1 tinha autoriza\u00e7\u00e3o de uso limitado. Segundo a estatal, a vacina recebeu o aval na 4\u00aa feira (30.dez.2020). A informa\u00e7\u00e3o foi divulgada em entrevista concedida …","og_url":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/","og_site_name":"Portal NPM","article_published_time":"2020-12-31T17:31:14+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg","type":"image\/jpeg"}],"author":"Genival Barbosa","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Genival Barbosa","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/","url":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/","name":"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm","isPartOf":{"@id":"https:\/\/portalnpm.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage"},"image":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage"},"thumbnailUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg","datePublished":"2020-12-31T17:31:14+00:00","dateModified":"2020-12-31T17:31:14+00:00","author":{"@id":"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294"},"breadcrumb":{"@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#primaryimage","url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg","contentUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/portalnpm.com\/index.php\/2020\/12\/31\/china-aprova-1a-vacina-anticovid-para-uso-geral-imunizante-e-da-sinopharm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/portalnpm.com\/"},{"@type":"ListItem","position":2,"name":"China aprova 1\u00aa vacina anticovid para uso geral; imunizante \u00e9 da Sinopharm"}]},{"@type":"WebSite","@id":"https:\/\/portalnpm.com\/#website","url":"https:\/\/portalnpm.com\/","name":"Portal NPM","description":"Not\u00edcias em Primeira M\u00e3o","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/portalnpm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/portalnpm.com\/#\/schema\/person\/49313e563cfdefcc167f1ee4c017c294","name":"Genival Barbosa","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/portalnpm.com\/#\/schema\/person\/image\/","url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg","contentUrl":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/02\/avatar_user_2_1707743258-96x96.jpeg","caption":"Genival Barbosa"},"url":"https:\/\/portalnpm.com\/index.php\/author\/genival\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/portalnpm.com\/wp-content\/uploads\/2024\/01\/BB1cno7n.jpeg","_links":{"self":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts\/60916"}],"collection":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/comments?post=60916"}],"version-history":[{"count":0,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/posts\/60916\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/media\/60917"}],"wp:attachment":[{"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/media?parent=60916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/categories?post=60916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/portalnpm.com\/index.php\/wp-json\/wp\/v2\/tags?post=60916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}